Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.

Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company's stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund

Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 39.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company's stock after selling 5,932 shares during the quarter. Exchange

FNY Investment Advisers LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ: EXAS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,500 shares of the medical research company's stock, valued at approximately $2,894,000. Exact Sciences accounts for about

Banque Pictet and Cie SA decreased its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 77.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,415 shares of the medical research company's stock after selling 151,772 shares

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.

Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their

ArrowMark Colorado Holdings LLC boosted its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 23.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 597,931 shares of the medical research company's stock after purchasing an additional 113,603 shares during the

Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.